The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Key advances in FL management expected to change practice over the next five years
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, discusses the evolving treatment landscape in follicular lymphoma (FL), highlighting the growing role of bispecific antibodies and combination therapies. Prof. Linton emphasizes that a key future challenge will be selecting and sequencing these therapies, as current biomarkers cannot reliably predict individual patient risk or treatment benefit. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s an interesting question. There’s going to be a number of changes, right? In the UK, we are on the cusp of NICE approvals, hopefully, of these combination therapies. So we’ve, you know, Tafa R-squared and Epcor R-squared are both going through. We’ve recently had epcoritamab approved. So we’re definitely seeing bispecific antibodies being part of the treatment landscape for relapse disease...
That’s an interesting question. There’s going to be a number of changes, right? In the UK, we are on the cusp of NICE approvals, hopefully, of these combination therapies. So we’ve, you know, Tafa R-squared and Epcor R-squared are both going through. We’ve recently had epcoritamab approved. So we’re definitely seeing bispecific antibodies being part of the treatment landscape for relapse disease. The trials are obviously moving those bispecs into first line and the anticipation is that they will show some superiority over standard immunochemotherapy and I think that’s then going to create the biggest challenge of trying to select patients who might require these therapies because at moment, one of the challenges we’ve got in follicular lymphoma is we can’t predict individual patient risk at baseline. So our prognostic biomarkers are completely useless in terms of predicting individual risk or treatment benefit. So we face a situation where we’re going to have many more therapies, and we haven’t even talked about CAR-T, but we’re going to have many more therapies on the treatment landscape and our real challenge is going to be how do we select them, when do we select them, how do we sequence those patients or those therapies but we will definitely have more treatments hopefully available to inform that decision.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
